Historical Stock Price
ACAD historical stock prices picture
Acadia Pharmaceuticals (ACAD) has the following price history information. Looking back at ACAD historical stock prices for the last five trading days, on August 08, 2022, ACAD opened at $16.03, traded as high as $16.97 and as low as $16.03, and closed at $16.62. Trading volume was a total of 2.06M shares. On August 09, 2022, ACAD opened at $16.60, traded as high as $16.83 and as low as $15.21, and closed at $16.22. Trading volume was a total of 3.04M shares. On August 10, 2022, ACAD opened at $16.58, traded as high as $16.66 and as low as $15.65, and closed at $16.15. Trading volume was a total of 1.60M shares. On August 11, 2022, ACAD opened at $16.11, traded as high as $16.28 and as low as $15.56, and closed at $15.74. Trading volume was a total of 1.44M shares. On August 12, 2022, ACAD opened at $15.88, traded as high as $16.43 and as low as $15.73, and closed at $16.40. Trading volume was a total of 1.37M shares.

ACAD Historical Stock Prices By Date:

ACAD historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into Acadia Pharmaceuticals shares, starting with a $10,000 purchase of ACAD, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 08/14/2012
End date: 08/12/2022
Start price/share: $1.70
End price/share: $16.40
Dividends collected/share: $0.00
Total return: 864.71%
Average Annual Total Return: 25.44%
Starting investment: $10,000.00
Ending investment: $96,462.93
Years: 10.00
Date Open High Low Close Volume
08/08/2022 $16.03 $16.97 $16.03 $16.62 2.06M
08/09/2022 $16.60 $16.83 $15.21 $16.22 3.04M
08/10/2022 $16.58 $16.66 $15.65 $16.15 1.60M
08/11/2022 $16.11 $16.28 $15.56 $15.74 1.44M
08/12/2022 $15.88 $16.43 $15.73 $16.40 1.37M
Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system disorders. Co. has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist/antagonist, targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.
Date Close
08/08/2022$16.62
08/09/2022$16.22
08/10/2022$16.15
08/11/2022$15.74
08/12/2022$16.40
ACAD is categorized under the Healthcare sector; below are some other companies in the same sector:

ACER Historical Stock Prices
ACET Historical Stock Prices
ACHC Historical Stock Prices
ACHN Historical Stock Prices
ACHV Historical Stock Prices
ACOR Historical Stock Prices
ACRS Historical Stock Prices
ACRX Historical Stock Prices
ACST Historical Stock Prices
ACT Historical Stock Prices

Also explore: ACAD shares outstanding history

Email EnvelopeFree ACAD Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts


ACAD Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.